Filtern
Volltext vorhanden
- nein (3) (entfernen)
Erscheinungsjahr
- 2017 (3) (entfernen)
Dokumenttyp
Sprache
- Englisch (3) (entfernen)
Gehört zur Bibliographie
- ja (3)
Schlagworte
- Antisense agents (1)
- Argonaute 2 protein (1)
- Drug design (1)
- Drug discovery (1)
- Small-molecule miRNA modulators (1)
- miRNA (1)
- miRNA inhibitors (1)
- miRNA seed region (1)
- miRNA-Argonaute 2 protein complex (1)
- microRNA (1)
Institut
Preface
(2017)
miRNA Targeting Drugs
(2017)
Only 20 years after the discovery of small non-coding, single-stranded ribonucleic acids, so-called microRNAs (miRNAs), as post-transcriptional gene regulators, the first miRNA-targeting drug Miravirsen for the treatment of hepatitis C has been successfully tested in clinical Phase II trials. Addressing miRNAs as drug targets may enable the cure, or at least the treatment of diseases, which presently seems impossible. However, due to miRNAs’ chemical structure, generation of potential drug molecules with necessary pharmacokinetic properties is still challenging and requires a re-thinking of the drug discovery process. Therefore, this chapter highlights the potential of miRNAs as drug targets, discusses the challenges, and tries to give a complete overview of recent strategies in miRNA drug discovery.
microRNAs (miRNAs) have been identified as high-value drug targets. A widely applied strategy in miRNA inhibition is the use of antisense agents. However, it has been shown that oligonucleotides are poorly cell permeable because of their complex chemical structure and due to their negatively charged backbone. Consequently, the general application of oligonucleotides in therapy is limited. Since miRNAs’ functions are executed exclusively by the Argonaute 2 protein, we therefore describe a protocol for the design of a novel miRNA inhibitor class: antagonists of the miRNA-Argonaute 2 protein complex, so-called anti-miR-AGOs, that not only block the crucial binding site of the target miRNA but also bind to the protein’s active site. Due to their lower molecular weight and, thus, more drug-like chemical structure, the novel inhibitor class may show better pharmacokinetic properties than reported oligonucleotide inhibitors, enabling them for potential therapeutic use.